Endocrine disruptor assessment list

Endocrine disruptor assessment list

Endocrine disruptor assessment list

ECHA’s endocrine disruptor (ED) assessment list includes the substances undergoing an ED assessment that have been brought for discussion to ECHA’s ED Expert Group.

Explanatory note

Inclusion in the list means that an informal hazard assessment for endocrine-disrupting properties either is under development or has been completed since February 2013.

For each substance, the table shows the assessing or evaluating Member State (submitter), the outcome from the assessment, and the date of the latest update to the list entry.

Other process details and hazard assessment outcome documents are also available and can be accessed through the ‘Details’ icon.

One possible outcome of such an assessment is that a substance is considered not to have ED properties.

If the outcome is that the substance is considered to have ED properties, confirmation through the formal risk management and decision-making processes under is needed before any regulatory action can be taken due to these properties.

The intentions of authorities to submit a dossier to the formal REACH and CLP processes are notified through the Registry of Intentions. All biocidal active substances have to undergo a formal ED assessment. You can see the status of biocides assessments on the Biocidal Active Substances page.


The information and views set out in the ED assessment list and in the hazard assessment outcome documents are those of the evaluating authority and do not necessarily reflect the position or opinion of the other Member States or ECHA. Neither ECHA nor the evaluating authority nor any person acting on either of their behalves may be held liable for the use, which may be made of the information contained therein. Statements made or information contained in the documents are without prejudice to any formal regulatory activities that ECHA or the Member States may initiate at a later stage. ED assessments and their outcomes are compiled on the basis of information available by the date of the publication of the document.


EC / List no: 201-248-4 CAS no: 80-08-0
Endocrine disruption
Date of intention
Date of hazard assessment
Hazard assessment outcome document
According to the SEv conclusion the initial ED concern cannot be rejected. There is weak evidence from SAR/QSAR and read across that dapsone binds to the ER and might exert endocrine effects. Data availability is very limited in general, also with respect to in vivo data. Further in vitro and in vivo data would be needed to clarify the concern. Data on BPS from the ongoing substance evaluation could also provide relevant information.

However, evidence for a probable exposure is not sufficient. Dapsone is not detected in the environment (few monitoring studies) and the current uses are all industrial and closed systems, predicted emissions are stated to be extremely low. Also, here data availability was limited.

In total, the evidence for both ED and exposure are too weak to justify data requests. This was discussed in the ED EG and considered that requests to clarify an ED concern would not be justified if there is no indication for a relevant exposure. In particular as only in silico evidence on CF level 1 support an ED concern.
Submitter organisation
Federal Institute for Occupational Safety and Health
Submitter email
Submitter phone
Submitter address
Federal Institute for Occupational Safety and Health; Division 5 "Federal Office for Chemicals"

Friedrich-Henkel-Weg 1-25; 44149 Dortmund
Latest update
First published